Table 2.
Univariate and multivariate analyses for breast cancer-specific survival
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HRs (95% CI) | P value | HRs (95% CI) | P value | |
| A. Hormone receptor-positive | ||||
| Pathological stage | .001 | .001 | ||
| Stage I | 1.00 | 1.00 | ||
| Stage II | 2.81 (1.82–4.34) | 1.81 (0.87–3.76) | ||
| Stage III | 14.34 (9.50–21.67) | 5.99 (2.34–15.34) | ||
| Tumor size: > 5 vs. ≤ 5 cm | 6.82 (4.81–9.68) | .001 | 1.59 (0.83–3.03) | .159 |
| LNR: Above vs. Below mean | 4.10 (3.07–5.47) | .001 | 1.24 (0.64–2.38) | .527 |
| Histological grade: G3 vs. G1/2 | 4.20 (3.14–5.60) | .001 | 3.41 (2.04–5.69) | .001 |
| Lymphatic invasion: Yes vs. No | 3.28 (2.44–4.41) | .001 | 1.65 (0.94–2.89) | .079 |
| Vascular invasion: Yes vs. No | 2.70 (1.94–3.75) | .001 | 0.79 (0.42–1.49) | .471 |
| Ki-67: < 14 vs. ≥ 14% | 0.54 (0.34–0.84) | .006 | 0.95 (0.57–1.56) | .825 |
| HER2: Low vs. IHC 0 | 0.61 (0.44–0.85) | .003 | 0.72 (0.44–1.17) | .186 |
| B. Hormone receptor-negative | ||||
| Pathological stage | .001 | .001 | ||
| Stage I | 1.00 | 1.00 | ||
| Stage II | 2.80 (1.89–4.14) | 2.03 (1.35–3.05) | ||
| Stage III | 12.95 (8.77–19.13) | 3.95 (2.34–6.63) | ||
| Tumor size: > 5 vs. ≤ 5 cm | 5.38 (3.97–7.29) | .001 | 1.94 (1.38–2.74) | .001 |
| LNR: Above vs. Below mean | 4.89 (3.83–6.26) | .001 | 1.92 (1.37–2.67) | .001 |
| Histological grade: G3 vs. G1/2 | 1.29 (0.95–1.73) | .102 | ||
| Lymphatic invasion: Yes vs. No | 4.27 (3.29–5.53) | .001 | 1.74 (1.23–2.46) | .006 |
| Vascular invasion: Yes vs. No | 3.88 (2.96–5.09) | .001 | 1.38 (0.99–0.19) | .132 |
| Ki-67: < 14 vs. ≥ 14% | 0.90 (0.54–1.49) | .691 | ||
| HER2: Low vs. IHC 0 | 0.69 (0.50–0.95) | .023 | 0.68 (0.49–0.93) | .019 |